JP2014526554A5 - - Google Patents

Download PDF

Info

Publication number
JP2014526554A5
JP2014526554A5 JP2014531936A JP2014531936A JP2014526554A5 JP 2014526554 A5 JP2014526554 A5 JP 2014526554A5 JP 2014531936 A JP2014531936 A JP 2014531936A JP 2014531936 A JP2014531936 A JP 2014531936A JP 2014526554 A5 JP2014526554 A5 JP 2014526554A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
compound
group
alkyl
diluents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014531936A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014526554A (ja
JP6100786B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/056186 external-priority patent/WO2013043778A1/en
Publication of JP2014526554A publication Critical patent/JP2014526554A/ja
Publication of JP2014526554A5 publication Critical patent/JP2014526554A5/ja
Application granted granted Critical
Publication of JP6100786B2 publication Critical patent/JP6100786B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014531936A 2011-09-21 2012-09-20 抗ウイルス活性を有する新規ベツリン酸誘導体 Expired - Fee Related JP6100786B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161537099P 2011-09-21 2011-09-21
US61/537,099 2011-09-21
PCT/US2012/056186 WO2013043778A1 (en) 2011-09-21 2012-09-20 Novel betulinic acid derivatives with antiviral activity

Publications (3)

Publication Number Publication Date
JP2014526554A JP2014526554A (ja) 2014-10-06
JP2014526554A5 true JP2014526554A5 (cg-RX-API-DMAC7.html) 2015-11-05
JP6100786B2 JP6100786B2 (ja) 2017-03-22

Family

ID=46964090

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014531936A Expired - Fee Related JP6100786B2 (ja) 2011-09-21 2012-09-20 抗ウイルス活性を有する新規ベツリン酸誘導体

Country Status (15)

Country Link
US (1) US8754069B2 (cg-RX-API-DMAC7.html)
EP (1) EP2758419B8 (cg-RX-API-DMAC7.html)
JP (1) JP6100786B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140069167A (cg-RX-API-DMAC7.html)
CN (1) CN103814042B (cg-RX-API-DMAC7.html)
AU (1) AU2012312485B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014006559A2 (cg-RX-API-DMAC7.html)
CA (1) CA2849475A1 (cg-RX-API-DMAC7.html)
EA (1) EA023463B1 (cg-RX-API-DMAC7.html)
ES (1) ES2611727T3 (cg-RX-API-DMAC7.html)
IL (1) IL231421A (cg-RX-API-DMAC7.html)
MX (1) MX2014002936A (cg-RX-API-DMAC7.html)
SG (1) SG11201400331WA (cg-RX-API-DMAC7.html)
TW (1) TW201317255A (cg-RX-API-DMAC7.html)
WO (1) WO2013043778A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906889B2 (en) 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
US20180094019A1 (en) * 2015-04-14 2018-04-05 ViiV Healthcare UK (No.4) Limited Crystalline forms of modified triterpenoid hydrochloride salts with hiv maturation inhibitor activity
EP3328876A1 (en) 2015-07-28 2018-06-06 Glaxosmithkline Intellectual Property (No. 2) Limited Betuin derivatives for preventing or treating hiv infections
CA2993758A1 (en) 2015-07-28 2017-02-02 Glaxosmithkline Intellectual Property (No.2) Limited Betuin derivatives for preventing or treating hiv infections
JP2018528231A (ja) 2015-09-24 2018-09-27 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited Hiv成熟阻害活性を有する化合物
CA3011616A1 (en) 2016-01-20 2017-07-27 Glaxosmithkline Intellectual Property (No.2) Limited Amine derivatives of lupanes with hiv maturation inhibitory activity
WO2018002847A1 (en) * 2016-06-30 2018-01-04 VIIV Healthcare UK (No.5) Limited Aza-substituted inhibitors of human immunodeficiency virus replication
ES2970042T3 (es) 2018-04-24 2024-05-24 Viiv Healthcare Uk No 5 Ltd Compuestos con actividad inhibidora de la maduración del VIH
EP3796900A4 (en) * 2018-06-29 2022-03-30 DFH Therapeutics TRITERPEN AMINE DERIVATIVES
US12275712B2 (en) * 2019-02-11 2025-04-15 Hetero Labs Limited Triterpene derivatives as HIV inhibitors
EP4103579A4 (en) * 2020-02-11 2024-05-01 Hetero Labs Limited NOVEL TRITEPENDENT DERIVATIVES AS HIV INHIBITORS

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5962527A (en) 1995-03-21 1999-10-05 The Board Of Trustees Of The University Of Illinois Method and composition for treating cancers
US5869535A (en) 1995-03-21 1999-02-09 The Board Of Trustees Of The University Of Illinois Method and composition for selectively inhibiting melanoma
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
US20050014730A1 (en) 2003-04-02 2005-01-20 Carlson Robert M. Anti-fungal formulation of triterpene and essential oil
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
AU2005224260A1 (en) 2004-03-17 2005-09-29 Panacos Pharmaceuticals, Inc. Pharmaceuticals salts of 3-O-(3',3'-dimethylsuccinyl) betulinic acid
TW200628161A (en) * 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
WO2008127364A2 (en) * 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
US20110144069A1 (en) 2006-10-16 2011-06-16 Myriad Genetics, Incorporated Compounds for treating viral infections
CA2714049A1 (en) * 2008-02-14 2009-08-20 Virochem Pharma Inc. Novel 17.beta. lupane derivatives
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
RS54239B1 (sr) 2010-06-04 2015-12-31 Bristol-Myers Squibb Company C-28 amidi modifikovanih derivata c-3 betulinske kiseline kao inhibitori sazrevanja hiv-a
CA2801487C (en) 2010-06-04 2017-12-05 Bristol-Myers Squibb Company Modified c-3 betulinic acid derivatives as hiv maturation inhibitors
CN103339141B (zh) 2011-01-31 2016-08-24 百时美施贵宝公司 作为hiv成熟抑制剂的c-3修饰的桦木酸衍生物的c-28胺
KR101886467B1 (ko) 2011-01-31 2018-08-07 비브 헬스케어 유케이 (넘버4) 리미티드 Hiv 성숙 억제 활성을 갖는 c-17 및 c-3 변형 트리테르페노이드

Similar Documents

Publication Publication Date Title
JP2014526554A5 (cg-RX-API-DMAC7.html)
IL274901B2 (en) Substituted nucleosides, nucleotides and analogs thereof
JP2017531038A5 (cg-RX-API-DMAC7.html)
WO2014106019A3 (en) Novel antiviral agents against hbv infection
JP2012526728A5 (cg-RX-API-DMAC7.html)
JP2013527243A5 (cg-RX-API-DMAC7.html)
JP2014500861A5 (cg-RX-API-DMAC7.html)
JP2015024998A5 (cg-RX-API-DMAC7.html)
EP3954679A3 (en) Amide compounds for the treatment of hiv infections
JP2013518107A5 (cg-RX-API-DMAC7.html)
JP2016530259A5 (cg-RX-API-DMAC7.html)
JP2013545785A5 (cg-RX-API-DMAC7.html)
JP2015510515A5 (cg-RX-API-DMAC7.html)
JP2013032389A5 (cg-RX-API-DMAC7.html)
JP2016510323A5 (cg-RX-API-DMAC7.html)
JP2012092103A5 (cg-RX-API-DMAC7.html)
EA201301158A1 (ru) Противовирусные соединения
JP2017537940A5 (cg-RX-API-DMAC7.html)
JP2017515901A5 (cg-RX-API-DMAC7.html)
JP2019526596A5 (cg-RX-API-DMAC7.html)
JP2015505296A5 (cg-RX-API-DMAC7.html)
NZ739248A (en) Inhibitors of hepatitis c virus
JP2013527242A5 (cg-RX-API-DMAC7.html)
JP2017523225A5 (cg-RX-API-DMAC7.html)
WO2012018534A3 (en) Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases